# AYESHA DIGITAL TWIN - MECHANISTIC BIOLOGY MOAT

**Date:** January 27, 2026  
**Purpose:** Transform Digital Twin from text Q&A â†’ Mechanistic Biology Visualization  
**MOAT:** Show HOW and WHY - the computational pipeline, biological mechanisms, Crispro's unique value  

---

## ğŸ¯ VISION: What is the Digital Twin?

### âŒ NOT This (ChatGPT-style text dump):
```
Q: "Will olaparib work for me?"
A: "Olaparib has 71% confidence because your MBD4 mutation creates synthetic lethality..."
```

### âœ… THIS (Mechanistic Biology Visualization):
```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ YOUR MUTATIONS â†’ BIOLOGICAL MECHANISM â†’ DRUG PREDICTION     â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                             â”‚
â”‚  MBD4 p.K431Nfs*54                                          â”‚
â”‚      â†“                                                      â”‚
â”‚  [Evo2 Scoring Pipeline]                                    â”‚
â”‚      â†“                                                      â”‚
â”‚  BER Pathway DISABLED                                       â”‚
â”‚      â†“                                                      â”‚
â”‚  [Synthetic Lethality Detection]                            â”‚
â”‚      â†“                                                      â”‚
â”‚  HR Dependency Created                                      â”‚
â”‚      â†“                                                      â”‚
â”‚  [S/P/E Framework]                                          â”‚
â”‚      â†“                                                      â”‚
â”‚  Olaparib 71% Confidence                                    â”‚
â”‚                                                             â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

---

## ğŸ§¬ DIGITAL TWIN ARCHITECTURE

### Core Principle:
**"Show the biology, not just the answer"**

Every prediction must show:
1. **Input:** Your mutation (genomic coordinates, protein change)
2. **Pipeline:** How we scored it (Evo2, Insights, Fusion)
3. **Biology:** What pathway is disrupted
4. **Mechanism:** Why this creates drug opportunity
5. **Output:** Confidence score with S/P/E breakdown

---

## ğŸ“Š MODULAR COMPONENTS

### 1. **Mutation â†’ Evo2 Scoring Visualizer**

**Component:** `MutationScoringPipeline.jsx`

**What it shows:**
```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ MBD4 p.K431Nfs*54 â†’ Evo2 Scoring                           â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                             â”‚
â”‚ 1. GENOMIC COORDINATES                                      â”‚
â”‚    chr3:129149435 A>del                                     â”‚
â”‚                                                             â”‚
â”‚ 2. SEQUENCE CONTEXT                                         â”‚
â”‚    [Show 100bp window with mutation highlighted]           â”‚
â”‚                                                             â”‚
â”‚ 3. EVO2 DELTA SCORE                                         â”‚
â”‚    â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–‘â–‘ -0.85 (90th percentile)            â”‚
â”‚    Interpretation: SEVERE disruption                        â”‚
â”‚                                                             â”‚
â”‚ 4. PROTEIN IMPACT                                           â”‚
â”‚    Frameshift â†’ Premature stop                              â”‚
â”‚    Loss of DNA glycosylase domain                           â”‚
â”‚                                                             â”‚
â”‚ 5. PATHWAY ASSIGNMENT                                       â”‚
â”‚    MBD4 â†’ BER (Base Excision Repair)                        â”‚
â”‚                                                             â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

**Data Flow:**
```jsx
<MutationScoringPipeline
  mutation={{
    gene: "MBD4",
    hgvs_p: "p.K431Nfs*54",
    chrom: "3",
    pos: 129149435,
    ref: "A",
    alt: "del"
  }}
  evo2Result={{
    delta: -0.85,
    percentile: 0.90,
    window: "ATCG...ATCG", // 100bp context
    interpretation: "SEVERE"
  }}
  proteinImpact={{
    type: "frameshift",
    domain_lost: "DNA glycosylase",
    functional_consequence: "Complete loss of BER activity"
  }}
/>
```

---

### 2. **Pathway Disruption Visualizer**

**Component:** `PathwayDisruptionMap.jsx`

**What it shows:**
```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ DNA REPAIR PATHWAYS - Ayesha's Profile                      â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                             â”‚
â”‚ BER (Base Excision Repair)                                  â”‚
â”‚ â”œâ”€ MBD4 âŒ LOST (frameshift)                                â”‚
â”‚ â”œâ”€ OGG1 âœ“ INTACT                                            â”‚
â”‚ â””â”€ MUTYH âœ“ INTACT                                           â”‚
â”‚ Status: âŒ PATHWAY DISABLED (1/3 genes lost, critical)      â”‚
â”‚                                                             â”‚
â”‚ HR (Homologous Recombination)                               â”‚
â”‚ â”œâ”€ BRCA1 âœ“ INTACT                                           â”‚
â”‚ â”œâ”€ BRCA2 âœ“ INTACT                                           â”‚
â”‚ â”œâ”€ RAD51C âœ“ INTACT                                          â”‚
â”‚ â””â”€ PALB2 âœ“ INTACT                                           â”‚
â”‚ Status: âœ“ PATHWAY INTACT (tumor depends on this!)          â”‚
â”‚                                                             â”‚
â”‚ TP53 Checkpoint                                             â”‚
â”‚ â””â”€ TP53 âŒ MUTANT (p.R273H)                                 â”‚
â”‚ Status: âŒ CHECKPOINT DISABLED                              â”‚
â”‚                                                             â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

**Data Flow:**
```jsx
<PathwayDisruptionMap
  pathways={{
    BER: {
      genes: [
        { name: "MBD4", status: "LOST", mutation: "p.K431Nfs*54" },
        { name: "OGG1", status: "INTACT" },
        { name: "MUTYH", status: "INTACT" }
      ],
      pathway_status: "DISABLED",
      critical: true
    },
    HR: {
      genes: [
        { name: "BRCA1", status: "INTACT" },
        { name: "BRCA2", status: "INTACT" }
      ],
      pathway_status: "INTACT",
      dependency: "HIGH" // Tumor depends on this!
    }
  }}
/>
```

---

### 3. **Synthetic Lethality Mechanism Visualizer**

**Component:** `SyntheticLethalityFlow.jsx`

**What it shows:**
```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ SYNTHETIC LETHALITY DETECTED                                â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                             â”‚
â”‚ NORMAL CELL:                                                â”‚
â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”     â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”                                â”‚
â”‚ â”‚   BER   â”‚  +  â”‚   HR    â”‚  =  âœ“ DNA REPAIRED             â”‚
â”‚ â”‚ (MBD4)  â”‚     â”‚ (BRCA)  â”‚                                â”‚
â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜     â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜                                â”‚
â”‚                                                             â”‚
â”‚ AYESHA'S TUMOR:                                             â”‚
â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”     â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”                                â”‚
â”‚ â”‚   BER   â”‚  +  â”‚   HR    â”‚  =  âš ï¸ SURVIVES ON HR          â”‚
â”‚ â”‚  âŒ LOST â”‚     â”‚ âœ“ INTACTâ”‚                                â”‚
â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜     â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜                                â”‚
â”‚                                                             â”‚
â”‚ ADD PARP INHIBITOR:                                         â”‚
â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”     â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”                                â”‚
â”‚ â”‚   BER   â”‚  +  â”‚   HR    â”‚  =  ğŸ’€ CELL DEATH              â”‚
â”‚ â”‚  âŒ LOST â”‚     â”‚âŒBLOCKEDâ”‚                                â”‚
â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜     â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜                                â”‚
â”‚                                                             â”‚
â”‚ MECHANISM:                                                  â”‚
â”‚ â€¢ BER loss (MBD4) â†’ Tumor depends on HR                     â”‚
â”‚ â€¢ PARP inhibitor â†’ Blocks HR                                â”‚
â”‚ â€¢ No BER + No HR â†’ Synthetic Lethality                      â”‚
â”‚                                                             â”‚
â”‚ CONFIDENCE: 71%                                             â”‚
â”‚ â”œâ”€ Sequence (S): 90% (severe MBD4 disruption)              â”‚
â”‚ â”œâ”€ Pathway (P): 100% (BERâ†’HR dependency confirmed)         â”‚
â”‚ â””â”€ Evidence (E): 0% (MBD4 rare, limited literature)        â”‚
â”‚                                                             â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

**Data Flow:**
```jsx
<SyntheticLethalityFlow
  slDetection={{
    detected: true,
    mechanism: "BER_HR_dependency",
    genes_detected: ["MBD4", "TP53"],
    pathway_disruption: {
      BER: 0.0,  // Completely lost
      HR: 1.0    // Intact (tumor depends on this)
    },
    suggested_therapy: "PARP inhibitor",
    confidence_breakdown: {
      sequence: 0.90,
      pathway: 1.00,
      evidence: 0.00
    }
  }}
  drug="olaparib"
  finalConfidence={0.71}
/>
```

---

### 4. **S/P/E Framework Visualizer**

**Component:** `SPEBreakdownCard.jsx`

**What it shows:**
```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ OLAPARIB - Confidence Breakdown                            â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                             â”‚
â”‚ FINAL CONFIDENCE: 71%                                       â”‚
â”‚ â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–‘â–‘â–‘â–‘â–‘â–‘                                        â”‚
â”‚                                                             â”‚
â”‚ HOW WE CALCULATED THIS:                                     â”‚
â”‚                                                             â”‚
â”‚ 1. SEQUENCE (S) - 35% weight                                â”‚
â”‚    â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–‘â–‘ 90%                                 â”‚
â”‚    â€¢ MBD4 Evo2 delta: -0.85 (90th percentile)              â”‚
â”‚    â€¢ TP53 Evo2 delta: -0.95 (95th percentile)              â”‚
â”‚    â€¢ Average: 92.5% â†’ Normalized to 90%                     â”‚
â”‚                                                             â”‚
â”‚ 2. PATHWAY (P) - 35% weight                                 â”‚
â”‚    â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“ 100%                                â”‚
â”‚    â€¢ MBD4 â†’ BER pathway (weight: 1.0)                       â”‚
â”‚    â€¢ BER loss â†’ HR dependency (SL detected)                 â”‚
â”‚    â€¢ PARP targets HR â†’ Perfect alignment                    â”‚
â”‚                                                             â”‚
â”‚ 3. EVIDENCE (E) - 30% weight                                â”‚
â”‚    â–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘ 0%                                  â”‚
â”‚    â€¢ ClinVar: VUS (no strong prior)                         â”‚
â”‚    â€¢ Literature: Limited (MBD4 rare)                        â”‚
â”‚    â€¢ Clinical trials: None (MBD4 too rare)                  â”‚
â”‚                                                             â”‚
â”‚ CALCULATION:                                                â”‚
â”‚ (0.35 Ã— 0.90) + (0.35 Ã— 1.00) + (0.30 Ã— 0.00)              â”‚
â”‚ = 0.315 + 0.350 + 0.000                                     â”‚
â”‚ = 0.665                                                     â”‚
â”‚                                                             â”‚
â”‚ BOOSTS APPLIED:                                             â”‚
â”‚ + SL Boost: +0.15 (synthetic lethality detected)           â”‚
â”‚ + PathwayAligned badge                                      â”‚
â”‚                                                             â”‚
â”‚ FINAL: 0.665 + 0.15 = 0.815 â†’ Capped at 0.71               â”‚
â”‚ (Confidence cap due to L1 data completeness)               â”‚
â”‚                                                             â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

**Data Flow:**
```jsx
<SPEBreakdownCard
  drug="olaparib"
  spe={{
    sequence: {
      score: 0.90,
      weight: 0.35,
      contribution: 0.315,
      details: [
        { gene: "MBD4", delta: -0.85, percentile: 0.90 },
        { gene: "TP53", delta: -0.95, percentile: 0.95 }
      ]
    },
    pathway: {
      score: 1.00,
      weight: 0.35,
      contribution: 0.350,
      details: {
        pathway: "BER",
        alignment: "PERFECT",
        sl_detected: true
      }
    },
    evidence: {
      score: 0.00,
      weight: 0.30,
      contribution: 0.000,
      details: {
        clinvar: "VUS",
        literature: "LIMITED",
        trials: "NONE"
      }
    }
  }}
  boosts={[
    { type: "SL", value: 0.15, reason: "Synthetic lethality detected" }
  ]}
  finalConfidence={0.71}
  confidenceCap={0.71}
  capReason="L1 data completeness"
/>
```

---

### 5. **Treatment Line Integration Visualizer**

**Component:** `TreatmentLineImpact.jsx`

**What it shows:**
```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ TREATMENT LINE IMPACT - Olaparib                           â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                             â”‚
â”‚ FIRST-LINE (Current):                                       â”‚
â”‚ Confidence: 71%                                             â”‚
â”‚ â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–‘â–‘â–‘â–‘â–‘â–‘                                        â”‚
â”‚ No resistance penalty (treatment-naive)                     â”‚
â”‚                                                             â”‚
â”‚ SECOND-LINE (If platinum fails):                            â”‚
â”‚ Confidence: 63% (-8% penalty)                               â”‚
â”‚ â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘                                        â”‚
â”‚ Penalty: DNA repair pathway cross-resistance                â”‚
â”‚ Reason: Platinum â†’ PARP cross-resistance via DDR            â”‚
â”‚                                                             â”‚
â”‚ THIRD-LINE (If platinum + PARP fail):                       â”‚
â”‚ Confidence: 55% (-16% penalty)                              â”‚
â”‚ â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘â–‘                                        â”‚
â”‚ Penalty: Cumulative resistance                              â”‚
â”‚ Reason: DDR pathway exhausted                               â”‚
â”‚                                                             â”‚
â”‚ MECHANISM:                                                  â”‚
â”‚ â€¢ Platinum damages DNA â†’ Selects for DDR upregulation      â”‚
â”‚ â€¢ PARP inhibitor targets DDR â†’ Cross-resistance            â”‚
â”‚ â€¢ Each line reduces PARP sensitivity                        â”‚
â”‚                                                             â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

---

### 6. **Holistic Score Integration**

**Component:** `HolisticMechanismCard.jsx`

**What it shows:**
```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ HOLISTIC FEASIBILITY - Trial NCT12345678                   â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                             â”‚
â”‚ OVERALL SCORE: 78%                                          â”‚
â”‚ â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–‘â–‘â–‘â–‘â–‘                                        â”‚
â”‚                                                             â”‚
â”‚ BREAKDOWN:                                                  â”‚
â”‚                                                             â”‚
â”‚ 1. MECHANISM FIT (50% weight): 85%                          â”‚
â”‚    â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–‘â–‘â–‘                                     â”‚
â”‚    â€¢ Drug: Olaparib (PARP inhibitor)                        â”‚
â”‚    â€¢ Your biology: MBD4 loss â†’ HR dependency                â”‚
â”‚    â€¢ Alignment: PERFECT (SL mechanism)                      â”‚
â”‚                                                             â”‚
â”‚ 2. ELIGIBILITY (30% weight): 70%                            â”‚
â”‚    â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–‘â–‘â–‘â–‘â–‘â–‘                                     â”‚
â”‚    â€¢ Stage IVB: âœ“ Eligible                                  â”‚
â”‚    â€¢ PD-L1 CPSâ‰¥1: âœ“ Met (CPS=10)                            â”‚
â”‚    â€¢ Prior lines: âœ“ Treatment-naive                         â”‚
â”‚                                                             â”‚
â”‚ 3. PGX SAFETY (20% weight): 65%                             â”‚
â”‚    â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â–‘â–‘â–‘â–‘â–‘â–‘â–‘                                     â”‚
â”‚    â€¢ No DPYD variants: âœ“ Safe                               â”‚
â”‚    â€¢ No UGT1A1 variants: âœ“ Safe                             â”‚
â”‚    â€¢ TPMT: âš ï¸ Intermediate metabolizer                      â”‚
â”‚                                                             â”‚
â”‚ CALCULATION:                                                â”‚
â”‚ (0.50 Ã— 0.85) + (0.30 Ã— 0.70) + (0.20 Ã— 0.65)              â”‚
â”‚ = 0.425 + 0.210 + 0.130                                     â”‚
â”‚ = 0.765 â†’ 78%                                               â”‚
â”‚                                                             â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

---

## ğŸ¯ DIGITAL TWIN PAGE STRUCTURE

### Main Page: `AyeshaDigitalTwin.jsx`

```jsx
<Container>
  {/* Hero Section */}
  <Box>
    <Typography variant="h3">Your Digital Twin</Typography>
    <Typography variant="body1">
      See the biology behind every prediction
    </Typography>
  </Box>
  
  {/* Section 1: Your Mutations */}
  <MutationScoringPipeline mutations={ayeshaMutations} />
  
  {/* Section 2: Pathway Disruption */}
  <PathwayDisruptionMap pathways={pathwayAnalysis} />
  
  {/* Section 3: Synthetic Lethality */}
  <SyntheticLethalityFlow slDetection={slResult} />
  
  {/* Section 4: Drug Predictions */}
  <Grid container spacing={3}>
    {drugs.map(drug => (
      <Grid item xs={12} md={6}>
        <SPEBreakdownCard drug={drug} />
      </Grid>
    ))}
  </Grid>
  
  {/* Section 5: Treatment Line Impact */}
  <TreatmentLineImpact drugs={drugs} />
  
  {/* Section 6: Trial Matching */}
  <Grid container spacing={3}>
    {trials.map(trial => (
      <Grid item xs={12}>
        <HolisticMechanismCard trial={trial} />
      </Grid>
    ))}
  </Grid>
</Container>
```

---

## ğŸ“‹ COMPONENT REUSE STRATEGY

### Existing Components to Integrate:

| Component | Location | Use In Digital Twin |
|-----------|----------|---------------------|
| `HolisticScoreCard.jsx` | `components/trials/` | Trial mechanism fit |
| `SyntheticLethalityCard.jsx` | `components/SyntheticLethality/` | SL mechanism flow |
| `TreatmentLineProvenance.jsx` | `components/` | Treatment line impact |
| `SAETreatmentLineChips.jsx` | `components/` | Resistance visualization |
| `PathwayAlignmentCard.jsx` | `components/ddr/` | Pathway disruption |
| `Evo2ScoringCard.jsx` | `components/genomic-analysis/` | Mutation scoring |

---

## ğŸš€ IMPLEMENTATION PLAN

### Phase 1: Core Mechanism Visualizers (4 hours)
1. Create `MutationScoringPipeline.jsx` (1.5 hours)
2. Create `PathwayDisruptionMap.jsx` (1 hour)
3. Create `SyntheticLethalityFlow.jsx` (1.5 hours)

### Phase 2: S/P/E Integration (3 hours)
1. Create `SPEBreakdownCard.jsx` (2 hours)
2. Integrate with existing drug cards (1 hour)

### Phase 3: Treatment Line + Holistic (3 hours)
1. Create `TreatmentLineImpact.jsx` (1.5 hours)
2. Create `HolisticMechanismCard.jsx` (1.5 hours)

### Phase 4: Main Page Assembly (2 hours)
1. Create `AyeshaDigitalTwin.jsx` (1 hour)
2. Wire all components together (1 hour)

**Total Time:** 12 hours

---

## ğŸ¯ SUCCESS CRITERIA

**Digital Twin is successful when:**
1. âœ… Every prediction shows HOW (computational pipeline)
2. âœ… Every prediction shows WHY (biological mechanism)
3. âœ… User can trace: Mutation â†’ Evo2 â†’ Pathway â†’ SL â†’ Drug
4. âœ… S/P/E breakdown visible for every drug
5. âœ… Treatment line impact shown mechanistically
6. âœ… Trial matching shows mechanism fit, not just eligibility

---

**Status:** ğŸ¯ **READY TO BUILD**  
**Next Step:** Create Phase 1 components (Mutation Scoring, Pathway Disruption, SL Flow)
